Cybin is a biopharmaceutical company developing deuterated psychedelic compounds. CYB003, a deuterated psilocin analog, is in Phase 3 trials (NCT06564818) for major depressive disorder. Primary completion estimated August 2026. One of the few companies to reach Phase 3 with a psychedelic compound.